Abbott Laboratories EVP Mary Moreland sells $406,000 in shares

On November 5, 2026, Mary K. Moreland, the Executive Vice President at Abbott Laboratories, sold 3,500 of the company's common shares. The transaction, disclosed in a recent SEC filing, netted her a total of $406,000, with each share priced at $116.00. Notably, this sale took place at a price higher than the current stock value of $109.93, which has demonstrated impressive growth, increasing by 28% over the last six months.

Abbott Laboratories' valuation stands at a P/E ratio of 41.03 and a substantial market capitalization of $196.75 billion. Post the sale, Ms. Moreland retains a personal stake of 100,791 shares directly, along with an additional 17,345 shares held indirectly through the Abbott Laboratories Stock Retirement Trust. In terms of dividend payments, the company has consistently paid dividends for 56 consecutive years, offering a yield of 2.29%.

For those interested in a comprehensive understanding of Abbott's performance, a Pro Research Report is available, detailing the company's performance alongside 1,400 other US equities. Meanwhile, Abbott Laboratories reported its third-quarter 2026 adjusted earnings of $1.42 per share, meeting expectations set by Wall Street. Revenue for the quarter stood at $13.01 billion, slightly surpassing forecasts.

Although the company experienced a 7% increase in sales and a 9% rise in adjusted earnings per share compared to the previous year, it lowered its full-year revenue growth guidance to approximately 6%, down from the previously anticipated range of 6.5% to 7.5%. In light of these developments, Argus reduced its rating on Abbott’s stock to Hold from Buy, citing challenges such as reimbursement uncertainties and competitive pressures.

StoneX maintains a Buy rating with a target price of $120, while Mizuho has retained a Neutral rating with a $115 target, pointing to a decline in the international Diabetes segment. BTIG has also revised its price target to $125 from $134, retaining a Buy rating, following Abbott's decision to spin off its Nutrition business by the end of 2027.

These updates paint a mixed picture of Abbott Laboratories, with analysts evaluating various factors that could influence the company's short-term performance.